27. Pharmacokinetics/Pharmacodynamics Expert Meeting
From May 15 till May 17, 2025
Event location: Bad Duerkheim/Pfalz (Link)
Presentations and associated discussions will focus on the following topics:
- Actionable vs. Non-Actionable Genetic Diversity
- The Evolution of Clinical Pharmacology Studies and Examples of Innovative Study Designs
- Evidence Generation in Rare Diseases – From Key Challenges to Innovative Solutions
We look forward to seeing you in Bad Duerkheim in May 2025.
Kind regards,
Dr. Nele Mueller-Plock
on behalf of the Organizing Committee
The programme of the 27. Pharmacokinetics/Pharmacodynamics Expert Meeting
|
|
||
| 17:00–19:00 | Arrival | |
| 19:00 | Dinner | |
|
|
||
| 08:30 | Welcome Nele Mueller-Plock on behalf of the Organizing Committee |
|
|
Session 1 |
Actionable vs. non-actionable genetic diversity Session Chairs: Andreas Kovar, Corina Becker |
|
| 08:45 | Integrating Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics: Advantages of Pre-Therapeutic Panel
Testing Jesse Swen (Leiden University Medical Center) |
|
| 09:20 | Discussion | |
| 09:35 | Coffee Break | |
| 10:05 | Genetic Variability in PK — Strategic Assessment, Development Integration, and Regulatory
Perspectives Friederike Kanefendt (Bayer) |
|
| 10:40 | Discussion | |
| 10:55 | Recall studies based on actionable findings in the Estonian Biobank Lili Milani (University of Tartu) |
|
| 11:30 | Discussion | |
| 11:45 | Master / PhD students: Best presentation award (5 min presentation followed by 5 min discussion each) |
|
| 12:30 | Joint Lunch | |
|
Session 2 |
The Evolution of Clinical Pharmacology Studies and Examples of Innovative Study
Designs Session Chairs: Joachim Höchel, Tobias Pähler, Ben-Fillippo Krippendorff |
|
| 13:30 | Setting the scene Tobias Pähler (Sanofi) |
|
| 13:35 | Overview on the Evolution of Typical Clinical Pharmacology Study Designs and Development
Programs Gerd Mikus (Freie Universität Berlin) |
|
| 14:00 | Discussion | |
| 14:10 | Where are we Today? Examples of Modern Study Designs Outside Oncology Christian Friedrich (Bayer) & Stephan Glund (Boehringer Ingelheim) |
|
| 14:45 | Discussion | |
| 14:55 | Experiences with the Implementation of Project Optimus Derived Study Designs in Oncology Alexander Phipps (Bayer) |
|
| 15:20 | Discussion | |
| 15:30 | Coffee Break | |
| 16:00 | Virtual Patients Powered by QSP Optimize Clinical Pharmacology Studies Britta Wagenhuber (Sanofi) |
|
| 16:25 | Discussion | |
| 16:40 | Hans Günter Schäfer Award and Best Presentation Award Moderated by Nele Mueller-Plock |
|
| 17:10 | End of Session | |
| 17:30 | Joint Jogging | |
| 19:15 | Evening Reception & Pre-Dinner Talk: Drugs in Popular Music — Examples from a Pharmaceutical Playlist Christiane Staiger |
|
| 20:00 | Dinner | |
|
|
||
|
Session 3 |
Evidence Generation in Rare Diseases — From Key Challenges to Innovative Solutions Session Chairs: Charlotte Kloft, Alexander Staab, Antje Walz |
|
| 09:00 | Rare Diseases — Challenges, Solutions and Roadblocks Holm Graeßner (University Hospital Tübingen) |
|
| 09:30 | Discussion | |
| 09:40 | Clinical Evidence Generation in Rare Diseases — Methodological Approaches Mats Karlsson (Uppsala University) |
|
| 10:10 | Discussion | |
| 10:20 | Coffee Break | |
| 10:50 | Utility of Modeling Approaches for Informing Spesolimab Drug Label in Generalized Pustular Psoriasis
(GPP) Christian Thoma & Sree Kurup (Boehringer Ingelheim) |
|
| 11:20 | Discussion | |
| 11:30 | Contrasting Evidence Generation: Pozelimab and Evinacumab for Treatment of Pediatric Ultra Rare
Diseases Lutz Harnisch (Regeneron) |
|
| 12:00 | Discussion | |
| 12:10 | Closing Remarks Nele Mueller-Plock on behalf of the Organizing Committee |
|
| 12:15 | Joint Lunch | |
| 13:00 | End of Meeting | |
